Comparison Of The Efficacy and Safety of Ixekizumab and Adalimumab

Annals of the Rheumatic Diseases
26 Feb, 2020 ,

Philip J Mease, conducted a study to compare efficacy and safety of ixekizumab to adalimumab in cases of disease-modifying antirheumatic drug-naïve patients suffering from active psoriatic arthritis and other symptoms. The researchers concluded that ixekizumab was far more superior adalimumab in the achievement of simultaneous improvement of joint and skin disease.